Lifeboat Foundation

Summary: The revolutionary field of bio-computing is making waves as DishBrain, a neural system combining 800,000 living brain cells, learns to play Pong. Recognizing the pressing need for ethical guidelines in this emerging domain, the pioneers behind DishBrain have joined forces with bioethicists in a study.

The research explores the moral considerations around biological computing systems and their potential consciousness. Beyond its innovation, the technology offers vast environmental benefits, potentially transforming the energy-consuming IT industry.

From the oxygen-carrying corpuscles in our blood to the branching neurons that govern our thoughts, our body is built of a dazzling variety of cells.

Researchers from institutions in Germany, Canada, Spain, and the US have published a comprehensive study of how many individual cells of each type there are in typical bodies.

Based on an exhaustive analysis of over 1,500 published sources, most adult males contain a total of around 36 trillion cells, while adult females tend to have some 28 trillion cells. A 10-year-old child, by comparison, would have in the region of 17 trillion.

Pigs with human kidneys? Brain-powered computer chips? Science is creating new kinds of living things – and our moral understanding needs to catch up fast.

Scientists discover a biomarker in stroke survivors, suggesting that chemical changes after stroke can lead to depression. The findings may pave the way toward treatment.

Summary: New research delves into the distinctive human trait of sequential memory, setting us apart from bonobos. A recent study has also highlighted the joy in chasing passions over accomplishments. Groundbreaking discoveries show the human brain’s computational prowess, mirroring high-powered computers.

Additionally, the footprint of Big Tobacco is evident in the modern American diet through the promotion of hyperpalatable foods. Lastly, understanding the range of mind’s visualization abilities, from hyperphantasia to aphantasia, opens avenues for innovative treatments.

With the demise of Roche’s gantenerumab in November 2022, the Alzheimer’s disease space became a two-horse race between Eisai and Biogen’s Leqembi (lecanemab) and Eli Lilly’s donanemab. One, Leqembi, received full FDA approval in July; the other, donanemab, is widely expected to secure the agency’s approval before the end of 2023.

With a potential combined market value of $30 billion, BioSpace takes a deep dive into the Phase III data supporting Eisai and Biogen’s Leqembi and Eli Lilly’s investigational donanemab.

Summary: Researchers pioneered a groundbreaking method called “CHOOSE” to investigate genes tied to autism spectrum disorder (ASD) within human tissue. This technique allows for simultaneous examination of key transcriptional regulator genes linked to autism in a single organoid.

Utilizing CHOOSE, the team pinpointed mutations in 36 genes known to heighten autism risk, shedding light on how they influence brain development. The revelations from these organoids mirrored clinical observations, underscoring the potential of this method in advancing our understanding of neurodevelopmental disorders.

Apple’s new “State of Mind” feature in the Health app is more than a tech update; it’s Apple’s foray into helping us understand our emotions. Beyond tracking physical activity with the Apple Watch, the company is now capturing our moods. This, combined with insights from a new Journal app (which Apple says will be woven into our life’s events and multimedia tapestry), aims to give a full picture of our daily experiences, both in body and mind.

Here’s how Apple envisions this feature will play out in real life.

Imagine a vacation in an unfamiliar city. At the start of your day, the Health app prompts you to record your mood. You describe it as “Very Pleasant” and indicate to the app that… More.

Continue reading “The Science Behind Apple’s ‘State Of Mind’ Feature, Explained By A Psychologist” »

Crispr used in mice to reverse vision loss 😀.

Qin and colleagues develop a genome-editing tool characterized by the versatility of prime editors and unconstrained PAM requirement of SpRY. In vivo gene corre.